Skip to main content
. 2022 Oct 25;90(1):405–417. doi: 10.3233/JAD-220440

Table 2.

Neuropathologic findings stratified by dementia presence

Variable No Dementia n = 72 Dementia n = 89 p
Brain weight, g 1200 (1120,1280) 1115 (1040,1215) <0.001
Braak stage IV (II,IV) V (IV,V) <0.001
Neuritic plaque score <0.001
  None, % 25/72 (35%) 6/89 (7%)
  Sparse, % 11/72 (15%) 13/89 (15%)
  Moderate, % 21/72 (29%) 37/89 (42%)
  Frequent, % 15/72 (21%) 33/89 (37%)
Diffuse plaque score <0.001
  None, % 13/64 (20%) 1/85 (1%)
  Sparse, % 8/64 (13%) 5/85 (6%)
  Moderate, % 14/64 (22%) 18/85 (21%)
  Frequent, % 29/64 (45%) 61/85 (72%)
Lewy body pathology 0.73
  None, % 55/72 (76%) 65/89 (73%)
  Lewy body disease, % 12/72 (17%) 19/89 (21%)
  Amygdala predominant Lewy bodies, % 5/72 (7%) 5/89 (6%)
LATE-NC in amygdala <0.001
  TDP-43 negative, % 25/54 (46%) 14/63 (22%)
  Rare, % 7/54 (13%) 1/63 (2%)
  TDP-43 positive, % 22/54 (41%) 48/63 (76%)
Cerebrovascular disease scales
  Kalaria score 4 (3, 7) 5 (3, 7) 0.71
  Strozyk score 2 (1, 2) 2 (1, 3) 0.51
  Dickson score 1 (0, 2) 1 (0, 2) 0.69
Arteriolosclerosis severity 2 (2, 3) 2 (2, 3) 0.748

Data are presented as median (25th percentile, 75th percentile) or proportion. Kruskal-Wallis rank sum test for numerical and ordered variables, Pearson’s Chi-squared test for categorical variables. g, grams; TDP-43, TAR DNA-binding protein of 43 kDa; LATE-NC, Limbic predominant age-related TDP-43 neuropathologic change in amygdala.